MedTrace Logo

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

NCT01034631 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2022-07-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.

Conditions

Interventions

DRUG

Everolimus

Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals

DRUG

BNC105P

BNC105P, up to 16 mg/m\^2

Sponsors & Collaborators

  • Bionomics Limited

    collaborator INDUSTRY

  • Hoosier Cancer Research Network

    lead OTHER

Principal Investigators

  • Thomas Hutson, D.O. · Hoosier Cancer Research Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States
  • Australia
  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01034631 on ClinicalTrials.gov